Table 1 Patient characteristics of four patients exhibiting relapse under therapy with intravenous rituximab 375 mg m−2 of body surface area
From: Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
Patients | 4 |
Gender | |
Male | 1 |
Female | 3 |
Age (years) | Mean: 67±6 |
Range: 68–72 | |
Prior therapy | |
Excision | 1 |
Radiotherapy | 1 |
Oral antibiotics | 1 |
Local steroids | 1 |
Other | 1 |
None | 0 |
Concomitant therapy | |
Excision | 4 |
Radiotherapy | 1 |
Chemotherapy | 1 |
Other | 0 |
None | 0 |
Subsequent therapy | |
Excision | 3 |
Radiotherapy | 2 |
Chemotherapy | 1 |
Intralesional rituximab | 1 |
Other | 1 |
None | 0 |
Histology of primary diagnosis | |
FBCL | 2 |
LBCL | 2 |
Best response to rituximab | |
CR | 3 |
PR | 1 |
SD | 0 |
PD | 0 |
Time to relapse (months) | Mean: 9±8 |
Range: 0–24 | |
Best response to following therapy | |
CR | 3 |
PR | 0 |
SD | 0 |
PD | 0 |
Follow-up (years) | 2±1 |
Current status | |
Alive with disease | 1 |
Alive without disease | 3 |
Died of lymphoma | 0 |
Died of unrelated cause | 0 |
